NASH Pathophysiology
Discover new insights into the NASH Pathophysiology, with all the complexity that includes multiple parallel hits.
Search Results for Fibrosis
Nash Treatment
Discover the latest advancements in NASH treatment tailored for healthcare professionals. Stay informed on cutting-edge research, innovative therapies, and best practices to optimize patient care in the evolving landscape of non-alcoholic steatohepatitis management.
Nash Diagnosis
Learn what is the criteria for a positive Nash diagnosis or NAFLD to be made,
Nash Comorbidities
NASH is “the liver manifestation of the metabolic syndrome (MetS)”. However, the consequences of NASH can extend well beyond just liver disease
NASH Epidemiology
The global epidemiology of NASH, : Discover the last update regarding the prevalence and variation of Nonalcoholic Steatohepatitis.
NASH Definitions
NASH Definitions and Etymology: Discover all the meanings
Machine learning-based approach to liver histology assessment
Manual histologic assessment is currently the accepted standard for diagnosing and monitoring disease progression in nonalcoholic steatohepatitis (NASH), but is limited by variability in interpretation and insensitivity to change. A. Taylor-Weiner et al. (PathAI, Boston, Massachusetts, USA) describe here a machine learning-based approach to liver...
Mechanisms, screening, prevention, and management of CVD in patients with NAFLD
Cardiovascular disease, rather than liver decompensation, remains the leading cause of morbidity and mortality in patients with NAFLD and NASH. A significant proportion of the cardiovascular risk in NASH is likely attributable to shared metabolic risk factors. Nevertheless, there is much interest in understanding the independent contribution...
Expert Perspective
Prof Sven Francque, Belgium, shares highlights from a recent paper in Nature reviews. PPARs regulate metabolism, inflammation and fibrosis, all of which determine NASH progression…
Sarcopenia: pathophysiological processes in NAFLD
A growing body of evidence places skeletal muscle and the muscle-liver axis at the center of the NAFLD pathogenic cascade. Skeletal muscle is implicated via its impact on insulin resistance and systemic inflammation. Population-based studies suggest that sarcopenia is an effect-modifier across the NAFLD spectrum and is tightly linked...
Nonalcoholic steatohepatitis: the role of PPARs (Peroxisome proliferator-activated receptors)
Prof Sven Francque, Belgium, shares highlights from a recent paper in Nature reviews. PPARs regulate metabolism, inflammation and fibrosis, all of which determine NASH progression. Both PPARα-β/δ dual agonism as well as PPARγ agonism have shown beneficial effects on liver histology in phase IIb clinical trials for NASH.
Cost-effectiveness of screening for NAFLD in patients with T2D
The authors hypothesized that screening for NAFLD in type 2 diabetes (T2D) patients, starting with ultrasound (US) and alanine aminotransferase (ALT) or aspartate aminotransferase (AST), followed with non-invasive testing for fibrosis to detect those most likely to have fibrosis stage ≥F2, is more cost effective than not screening this population...